NeuroSense Therapeutics Ltd. announced additional long-term overall survival data from its previously completed PARADIGM Phase 2b randomized, double-blind, placebo-controlled trial of PrimeC in amyotrophic lateral sclerosis (ALS). In an updated extended follow-up analysis, patients who received PrimeC continuously during the double-blind and open-label phases had an estimated median survival of 36.3 months versus 21.4 months for patients initially assigned to placebo who crossed over to active treatment; the log-rank test reported p=0.0218. A Cox model analysis reported a hazard ratio of 0.35 (95% CI 0.17–0.71; p=0.0037), corresponding to a 65% reduction in risk of death versus placebo. The results were reported as newly available additional analyses from the completed study, with no future presentation indicated.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202602180905PR_NEWS_USPR_____IO90383) on February 18, 2026, and is solely responsible for the information contained therein.
